CytomX Therapeutics Inc [CTMX] stock is trading at $5.37, down -0.37%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CTMX shares have gain 23.73% over the last week, with a monthly amount glided 30.66%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CytomX Therapeutics Inc [NASDAQ: CTMX] stock has seen the most recent analyst activity on January 20, 2026, when Guggenheim initiated its Buy rating and assigned the stock a price target of $10. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on September 22, 2025, and set its price target to $6. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $7 on July 31, 2025. H.C. Wainwright upgraded its rating to a Buy but $5 remained the price target by the analyst firm on May 15, 2025. In a note dated May 28, 2024, Piper Sandler upgraded an Overweight rating on this stock and boosted its target price from $2.25 to $3.50.
CytomX Therapeutics Inc [CTMX] stock has fluctuated between $0.40 and $5.70 over the past year. Currently, Wall Street analysts expect the stock to reach $8.75 within the next 12 months. CytomX Therapeutics Inc [NASDAQ: CTMX] shares were valued at $5.37 at the most recent close of the market. An investor can expect a potential return of 62.94% based on the average CTMX price forecast.
Analyzing the CTMX fundamentals
CytomX Therapeutics Inc [NASDAQ:CTMX] reported sales of 113.63M for the trailing twelve months, which represents a drop of -82.16%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.25%, and Net Profit Margin reading is 0.25%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.44 and Total Capital is 0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, CytomX Therapeutics Inc’s Current Ratio is 3.64. In addition, the Quick Ratio stands at 3.64 and the Cash Ratio stands at 0.83. Considering the valuation of this stock, the price to sales ratio is 8.01, the price to book ratio is 8.25 and price to earnings (TTM) ratio is 12.84.
Transactions by insiders
Recent insider trading involved McCarthy Sean A., CEO, that happened on Nov 06 ’25 when 0.1 million shares were sold. CEO, Sean McCarthy completed a deal on Nov 06 ’25 to buy 0.1 million shares. Meanwhile, Chief Financial Officer Ogden Christopher sold 10614.0 shares on Jun 16 ’25.
